arrow
Y

Yushi Ueki

niigata university
H指数:15
被引数:772

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prophylactic use of episil oral liquid to prevent oral mucositis during head and neck concurrent chemoradiotherapy: a prospective single-arm study

预防性使用Episil口腔液体以预防头颈部同期放化疗期间口腔黏膜炎:一项前瞻性单臂研究

2026-08-010
OA
Development of a novel prognostic assessment tool for recurrent respiratory papillomatosis

开发一种新型复发性呼吸道乳头状瘤病预后评估工具

2026-04-160
OAAI
Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study)

改良EXTREME方案与改良TPEx方案作为复发或转移性头颈鳞状细胞癌的一线治疗:一项多中心、开放标签、随机、探索性研究(TEMPER研究)

2026-02-090
OAAI
The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy

HER2-Low表达在涎腺导管癌中的影响:临床病理特征、生存结局及其与雄激素受体靶向治疗的关联

2025-06-010
PRE
Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data

同步放化疗联合每周低剂量卡铂用于顺铂不耐受的头颈部鳞状细胞癌患者的生存分析:基于2年随访数据的分析

2025-05-050
PRE
Parathyroid near-infrared autofluorescence differently benefits depending on the surgeon's skill for preventing from hypoparathyroidism after total thyroidectomy: A systematic review and meta-analysis

甲状旁腺近红外自体荧光根据外科医生的技术水平在预防全甲状腺切除术后甲状旁腺功能减退方面产生不同的益处:一项系统评价和荟萃分析

2025-04-240
OA
Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study)

通过综合分析头颈癌患者的预处理血浆外泌体mrna,鉴定生物标志物以预测nivolumab的治疗反应的全国多中心前瞻性研究 (BIONEXT研究)

2025-01-100
OAAI
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab

PD-L1表达作为使用pembrolizumab治疗的复发或转移性唾液腺癌患者的预测生物标志物

2024-08-270
OAAI
Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma

头颈部鳞状细胞癌中nivolumab反应的临床,基因组和免疫微环境决定因素

2024-07-291
OAAI
The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinoma

涎腺导管癌自主神经的临床病理及预后意义

2024-07-230
PRE
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling

通过综合分子谱分析鉴定涎腺导管癌的新型预后和预测生物标志物

2022-11-047
OAAI
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma

HER2-targeted或雄激素剥夺疗法在涎腺导管癌中的生存益处

2022-09-0619
OAAI
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy

EZH2和H3K27me3表达作为涎腺导管癌患者临床预后预测指标的作用: 一项大型系列研究,重点是雄激素阻断和HER2-Targeted联合治疗的相关性

2022-02-0315
OAAI
The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma

涎腺导管癌中adipophilin和脂肪酸合酶表达的临床病理意义

2020-02-269
OAAI
The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases
2018-09-259
OAAI